PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy

@inproceedings{Beelen2014PI3KAKTmTORPA,
  title={PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy},
  author={Karin Beelen and Laurien D C Hoefnagel and Mark Opdam and Jelle Wesseling and Joyce Sanders and Andrew D. Vincent and Paul J van Diest and Sabine Linn},
  booktitle={International journal of cancer},
  year={2014}
}
Both preclinical and clinical data suggest that activation of the PI3K/AKT/mTOR pathway in response to hormonal therapy results in acquired endocrine therapy resistance. We evaluated differences in activation of the PI3K/AKT/mTOR pathway in estrogen receptor α (ERα) positive primary and corresponding metastatic breast cancer tissues using immunohistochemistry for downstream activated proteins, like phosphorylated mTOR (p-mTOR), phosphorylated 4E Binding Protein 1 (p-4EBP1) and phosphorylated… CONTINUE READING